Novartis AG Net Income 2006-2018 | NVS

Novartis AG annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Novartis AG net income for the quarter ending September 30, 2018 was $1.623B, a 22.01% decline year-over-year.
  • Novartis AG net income for the twelve months ending September 30, 2018 was $13.392B, a 100.36% increase year-over-year.
  • Novartis AG annual net income for 2017 was $7.703B, a 14.76% increase from 2016.
  • Novartis AG annual net income for 2016 was $6.712B, a 62.26% decline from 2015.
  • Novartis AG annual net income for 2015 was $17.783B, a 74.17% increase from 2014.
Novartis AG Annual Net Income
(Millions of US $)
2017 $7,703
2016 $6,712
2015 $17,783
2014 $10,210
2013 $9,175
2012 $9,270
2011 $8,940
2010 $9,794
2009 $8,400
2008 $8,195
2007 $11,946
2006 $7,175
2005 $6,130
Novartis AG Quarterly Net Income
(Millions of US $)
Q3 2018 $1,623
Q2 2018 $7,768
Q1 2018 $2,025
Q4 2017 $1,976
Q3 2017 $2,081
Q2 2017 $1,980
Q1 2017 $1,666
Q4 2016 $957
Q3 2016 $1,940
Q2 2016 $1,804
Q1 2016 $2,011
Q4 2015 $1,054
Q3 2015 $1,888
Q2 2015 $1,836
Q1 2015 $13,005
Q4 2014 $1,491
Q3 2014 $3,223
Q2 2014 $2,555
Q1 2014 $2,941
Q4 2013 $2,029
Q3 2013 $2,232
Q2 2013 $2,516
Q1 2013 $2,398
Q4 2012 $1,985
Q3 2012 $2,390
Q2 2012 $2,648
Q1 2012 $2,247
Q4 2011 $1,002
Q3 2011 $2,464
Q2 2011 $2,704
Q1 2011 $2,770
Q4 2010 $2,169
Q3 2010 $2,275
Q2 2010 $2,417
Q1 2010 $2,933
Q4 2009 $2,305
Q3 2009 $2,098
Q2 2009 $2,035
Q1 2009 $1,962
Q4 2008 $1,539
Q3 2008 $2,090
Q2 2008 $2,249
Q1 2008 $2,317
Q4 2007 $904
Q3 2007 $6,865
Q2 2007 $2,008
Q1 2007 $2,169
Q4 2006 $1,654
Q3 2006 $1,867
Q2 2006 $1,707
Q1 2006 $1,947
Q4 2005 $1,350
Q3 2005 $1,659
Q2 2005 $1,640
Q1 2005 $1,481
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $204.655B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $396.345B 18.58
Pfizer (PFE) United States $262.998B 14.83
Merck (MRK) United States $205.854B 17.84
AbbVie (ABBV) United States $134.597B 11.95
Eli Lilly (LLY) United States $122.680B 21.57
Sanofi (SNY) France $112.713B 13.96
Novo Nordisk (NVO) Denmark $111.107B 18.04
AstraZeneca (AZN) United Kingdom $103.342B 12.83
GlaxoSmithKline (GSK) United Kingdom $101.256B 13.61
Bristol-Myers Squibb (BMY) United States $87.290B 14.38